GlassScriptPhysician profile
Maryam R Kashi
NPI 1467569533
$38,057.98
in general payments reported to CMS, 2019-2025
24 companies · $488 in 2025
The $488 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $508 · 2020: $3,762 · 2021: $3,222 · 2022: $139 · 2023: $26K · 2024: $3,950 · 2025: $488.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $27K · Food and Beverage: $2,050 · Education: $1,229.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $27,148.13 |
| Food and Beverage | $2,049.56 |
| Education | $1,228.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ferring Pharmaceuticals INC. | $32,311.61 | 2021-2025 | Rebyota |
| Allergan, INC. | $3,797.45 | 2019-2020 | |
| Celltrion USA INC. | $264.13 | 2024-2025 | Zymfentra, Vegzelma |
| Abbvie INC. | $248.27 | 2019-2025 | |
| Phathom Pharmaceuticals, INC. | $224.77 | 2023-2025 | Voquezna |
| Madrigal Pharmaceuticals | $177.75 | 2024-2025 | Rezdiffra |
| Regeneron Pharmaceuticals, INC. | $139.47 | 2022 | |
| Medical Device Business Services, INC. | $116.50 | 2019 | |
| Janssen Biotech, INC. | $110.47 | 2020-2023 | Stelara, Simponi, Remicade |
| Ironwood Pharmaceuticals, INC | $97.45 | 2020 | |
| Boston Scientific Corporation | $73.98 | 2023-2024 | |
| Pfizer INC. | $71.18 | 2021 | |
| Medtronic USA, INC. | $66.27 | 2019 | |
| Intra-Sana Laboratories | $51.89 | 2025 | Reltone 400 Mg, Reltone 200 Mg, Glycate |
| Nestle Healthcare Nutrition INC. | $47.25 | 2023 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axonics, INC. | $46.38 | 2024 | Axonics |
| Ardelyx, INC. | $42.24 | 2025 | Ibsrela |
| Iterative Scopes, INC. | $40.94 | 2024 | Skout |
| Mallinckrodt Hospital Products INC. | $33.30 | 2024 | Terlivaz |
| Genzyme Corporation | $23.43 | 2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $21.05 | 2025 | Xifaxan |
| Lilly USA, LLC | $19.40 | 2025 | Omvoh |
| Olympus America INC. | $17.89 | 2025 | Endoclot Phs |
| Covidien LP | $14.91 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maryam Kashi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.